Researchers uncover 'hidden key' to immunotherapy for intractable brain tumors

Researchers have uncovered a clue to why immune checkpoint inhibitors—cancer therapies that release the immune "brakes" exploited by tumors to evade attack—show limited efficacy in some brain tumors.

A KAIST research team found that B-cell and antibody responses initiated in tumor-draining lymph nodes, rather than T cells alone, are critical to the antitumor effects of anti-CTLA-4 therapy, opening a new avenue for treating intractable brain tumors. ...